An omics perspective on molecular biomarkers for diagnosis, prognosis, and therapeutics of cholangiocarcinoma

International Journal of Genomics

Volumn 2015, Issue , 2015, Pages

  Seeree, Pattaya ^a   Pearngam, Phorutai ^a   Kumkate, Supeecha ^a   Janvilisri, Tavan ^a  

^a Department of Biology Faculty of Science Mahidol University ^*  (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; DIAGNOSTIC TEST ACCURACY STUDY; GENOMICS; HUMAN; METABOLOMICS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SURVIVAL RATE; TRANSCRIPTOMICS;

EID: 84941670985     PISSN: 2314436X     EISSN: 23144378     Source Type: Journal    
DOI: 10.1155/2015/179528     Document Type: Review

References (216)

1. J.-N.Vauthey and L.H. Blumgart. Recent advances in themanagement of cholangiocarcinomas. Seminars in Liver Disease, vol. 14, no. 2, pp. 109-114, 1994
2. B. Blechacz and G. J. Gores. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology, vol. 48, no. 1, pp. 308-321, 2008
3. S. A. Khan, B. R. Davidson, R. Goldin et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut, vol. 51, supplement 6, pp. vi1-vi9, 2002
4. Y. Shaib and H. B. El-Serag. The epidemiology of cholangiocarcinoma. Seminars in Liver Disease, vol. 24, no. 2, pp. 115-125, 2004
5. B. Sripa and C. Pairojkul. Cholangiocarcinoma: lessons from Thailand. Current Opinion in Gastroenterology, vol. 24, no. 3, pp. 349-356, 2008
6. J. E. Everhart and C. E. Ruhl. Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas. Gastroenterology, vol. 136, no. 4, pp. 1134-1144, 2009
7. N. Razumilava and G. J. Gores. Cholangiocarcinoma. The Lancet, vol. 383, no. 9935, pp. 2168-2179, 2014
8. T. M. Welzel, B. I. Graubard, S. Zeuzem, H. B. El-Serag, J. A. Davila, and K. A. Mcglynn. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-medicare database. Hepatology, vol. 54, no. 2, pp. 463-471, 2011
9. T. Nakagohri, T. Kinoshita, M. Konishi, S. Takahashi, and N. Gotohda. Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma. World Journal of Surgery, vol. 32, no. 12, pp. 2675-2680, 2008
10. C. B. Rosen, J. K.Heimbach, and G. J.Gores. Liver transplantation for cholangiocarcinoma. Transplant International, vol. 23, no. 7, pp. 692-697, 2010
11. C.-Y. Chen, S.-C. Shiesh, H.-C. Tsao, and X.-Z. Lin. The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma-the influence of sampling time and hepatolithiasis. Hepato-Gastroenterology, vol. 49, no. 45, pp. 616-620, 2002
12. Y. Nakanuma and M. Sasaki. Expression of blood grouprelated antigens in the intrahepatic biliary tree and hepatocytes in normal livers and various hepatobiliary diseases. Hepatology, vol. 10, no. 2, pp. 174-178, 1989
13. A. Nakeeb, P. A. Lipsett, K. D. Lillemoe et al. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. The American Journal of Surgery, vol. 171, no. 1, pp. 147-152, 1996
14. R. P. Horgan and L. C. Kenny. Omic technologies: genomics, transcriptomics, proteomics and metabolomics. The Obstetrician & Gynaecologist, vol. 13, no. 3, pp. 189-195, 2011
15. E. F. Petricoin, K. C. Zoon, E. C. Kohn, J. C. Barrett, and L. A. Liotta. Clinical proteomics: translating benchside promise into bedside reality. Nature Reviews Drug Discovery, vol. 1, no. 9, pp. 683-695, 2002
16. D. Theodorescu and H. Mischak. Mass spectrometry based proteomics in urine biomarker discovery. World Journal of Urology, vol. 25, no. 5, pp. 435-443, 2007
17. W. P. Blackstock and M. P. Weir. Proteomics: quantitative and physical mapping of cellular proteins. Trends in Biotechnology, vol. 17, no. 3, pp. 121-127, 1999
18. J. R. Cantor and D. M. Sabatini. Cancer cell metabolism: one hallmark, many faces. Cancer Discovery, vol. 2, no. 10, pp. 881-898, 2012
19. C. V. Dang. Links between metabolism and cancer. Genes &Development 26 9 877-890, 2012
20. M. G. Vander Heiden. Targeting cancer metabolism: a therapeutic window opens. Nature Reviews Drug Discovery, vol. 10, no. 9, pp. 671-684, 2011
21. P. S. Ward and C. B. Thompson. Signaling in control of cell growth and metabolism. Cold Spring Harbor Perspectives in Biology, vol. 4, no. 7, Article ID a006783, 2012
22. E. G. B. Fritcher, B. R. Kipp, K. C.Halling et al. Amultivariable model using advanced cytologic methods for the evaluation of indeterminate pancreatobiliary strictures. Gastroenterology, vol. 136, no. 7, pp. 2180-2186, 2009
23. G. J. Gores. Cholangiocarcinoma: current concepts and insights. Hepatology, vol. 37, no. 5, pp. 961-969, 2003
24. H.Malhi and G. J. Gores. Review article: the modern diagnosis and therapy of cholangiocarcinoma. Alimentary Pharmacology andTherapeutics, vol. 23, no. 9, pp. 1287-1296, 2006
25. K. Homayounfar, B. Gunawan, S. Cameron et al. Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization. Human Pathology, vol. 40, no. 6, pp. 834-842, 2009
26. S. C. McKay, K. Unger, S. Pericleous et al. Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. HPB, vol. 13, no. 5, pp. 309-319, 2011
27. G.Miller, N.D. Socci, D.Dhall et al. Genomewide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. Journal of Experimental and Clinical Cancer Research, vol. 28, article 62, 2009
28. S. H. Koo, C. H. Ihm, K. C. Kwon, J. W. Park, J. M. Kim, and G. Kong. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Genetics and Cytogenetics, vol. 130, no. 1, pp. 22-28, 2001
29. H. Tsuda, S. Satarug, V. Bhudhisawasdi, T. Kihana, T. Sugimura, and S. Hirohashi. Cholangiocarcinomas in Japanese and Thai patients: difference in etiology and incidence of point mutation of the c-KI-ras proto-oncogene. Molecular Carcinogenesis, vol. 6, no. 4, pp. 266-269, 1992
30. S. Yoshida, T. Todoroki, Y. Ichikawa et al. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Research, vol. 55, no. 13, pp. 2756-2760, 1995
31. S. Dachrut, S. Banthaisong, M. Sripa et al. DNA copy-number loss on 1p36.1 harboring runx3 with promoter hypermethylation and associated loss of runx3 expression in liver flukeassociated intrahepatic cholangiocarcinoma. Asian Pacific Journal of Cancer Prevention, vol. 10, no. 4, pp. 575-582, 2009
32. T. Limpaiboon, S. Tapdara, P. Jearanaikoon, B. Sripa, and V. Bhudhisawasdi. Prognostic significance of microsatellite alterations at 1p36 in cholangiocarcinoma. World Journal of Gastroenterology, vol. 12, no. 27, pp. 4377-4382, 2006
33. K. Muenphon, T. Limpaiboon, P. Jearanaikoon, C. Pairojkul, B. Sripa, and V. Bhudhisawasdi. Amplification of chromosome 21q22.3 harboring trefoil factor family genes in liver fluke related cholangiocarcinoma is associated with poor prognosis. World Journal of Gastroenterology, vol. 12, no. 26, pp. 4143-4148, 2006
34. M.-A. Seol, I.-S. Chu, M.-J. Lee et al. Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentation of cholangiocarcinoma. BMC Cancer, vol. 11, article 78, 2011
35. N. Harada, T. Mizoi, M. Kinouchi et al. Introduction of antisense CD44s cDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. International Journal of Cancer, vol. 91, no. 1, pp. 67-75, 2001
36. H.G.Hass, O. Nehls, J. Jobst, A. Frilling, U.Vogel, and S. Kaiser. Identification of osteopontin as the most consistently overexpressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis. World Journal of Gastroenterology, vol. 14, no. 16, pp. 2501-2510, 2008
37. M. Tachibana, Y. Tonomoto, R. Hyakudomi et al. Expression and prognostic significance of EFNB2 and EphB4 genes in patients with oesophageal squamous cell carcinoma. Digestive and Liver Disease, vol. 39, no. 8, pp. 725-732, 2007
38. T.Kudoh and I. B.Dawid. Role of the iroquois3 homeobox gene in organizer formation. Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 14, pp. 7852-7857, 2001
39. J. M. Ordway, J. A. Bedell, R.W. Citek et al. Comprehensive DNA methylation profiling in a human cancer genome identifies novel epigenetic targets. Carcinogenesis, vol. 27, no. 12, pp. 2409-2423, 2006
40. I. Issemann and S.Green. Activation of amember of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, vol. 347, no. 6294, pp. 645-650, 1990
41. B.R.Kipp, E. G. Barr Fritcher, A.C.Clayton et al. Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. The Journal of Molecular Diagnostics, vol. 12, no. 6, pp. 780-786, 2010
42. T. Isa, S. Tomita, A. Nakachi et al. Analysis of microsatellite instability, K-ras genemutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepato-Gastroenterology, vol. 49, no. 45, pp. 604-608, 2002
43. W. Chan-On, M.-L. Nairismägi, C. K. Ong et al. Exome sequencing identifies distinctmutational patterns in liver flukerelated and non-infection-related bile duct cancers. Nature Genetics, vol. 45, no. 12, pp. 1474-1478, 2013
44. B. R. Kipp, E. G. B. Fritcher, A. C. Clayton et al. Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. Journal of Molecular Diagnostics, vol. 12, no. 6, pp. 780-786, 2010
45. K.Nakazawa, Y. Dobashi, S. Suzuki, H. Fujii, Y. Takeda, and A. Ooi. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. Journal of Pathology, vol. 206, no. 3, pp. 356-365, 2005
46. R. F.Xu, J. P. Sun, S.R.Zhang et al. KRAS and PIK3CAbut not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. Biomedicine and Pharmacotherapy, vol. 65, no. 1, pp. 22-26, 2011
47. H. Prenen, J. De Schutter, B. Jacobs et al. PIK3CAmutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clinical Cancer Research, vol. 15, no. 9, pp. 3184-3188, 2009
48. P. Laurent-Puig, A. Lievre, and H. Blons. Mutations and response to epidermal growth factor receptor Inhibitors. Clinical Cancer Research, vol. 15, no. 4, pp. 1133-1139, 2009
49. D. Yoshikawa, H. Ojima, A. Kokubu et al. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novelmolecular-targeted therapy against cholangiocarcinoma. British Journal of Cancer, vol. 100, no. 8, pp. 1257-1266, 2009
50. M. R. ODell, J. L. Huang, C. L. Whitney-Miller et al. Kras G12D and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Research, vol. 72, no. 6, pp. 1557-1567, 2012
51. V. Deshpande, A. Nduaguba, S. M. Zimmerman et al. Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer, vol. 11, article 60, 2011
52. M.-O. Riener, M. Bawohl, P.-A. Clavien, andW. Jochum. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes and Cancer, vol. 47, no. 5, pp. 363-367, 2008
53. C. Li, W. Shen, S. Shen, and Z. Ai. Gene expression patterns combined with bioinformatics analysis identify genes associated with cholangiocarcinoma. Computational Biology and Chemistry, vol. 47, pp. 192-197, 2013
54. R. Rice, D. P. C. Rice, and I. Thesleff. Foxc1 integrates Fgf and Bmp signalling independently of Twist or Noggin during calvarial bone development. DevelopmentalDynamics, vol. 233, no. 3, pp. 847-852, 2005
55. P. S. Ray, J.Wang, Y. Qu et al. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Research, vol. 70, no. 10, pp. 3870-3876, 2010
56. C. S. Merzdorf. Emerging roles for zic genes in early development. Developmental Dynamics, vol. 236, no. 4, pp. 922-940, 2007
57. L. Sussel, J. Kalamaras, D. J. Hartigan-OConnor et al. Mice lacking the homeodomain transcription factor Nkx2.2 have diabetes due to arrested differentiation of pancreatic cells. Development, vol. 125, no. 12, pp. 2213-2221, 1998
58. M. Price, D. Lazzaro, T. Pohl et al. Regional expression of the homeobox gene Nkx-2.2 in the developing mammalian forebrain. Neuron, vol. 8, no. 2, pp. 241-255, 1992
59. L. A. Owen, A. A. Kowalewski, and S. L. Lessnick. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewings sarcoma. PLoS ONE, vol. 3, no. 4, Article ID e1965, 2008
60. I. Subrungruang, C.Thawornkuno, C.-P. Porntip, C. Pairojkul, S. Wongkham, and S. Petmitr. Gene expression profiling of intrahepatic cholangiocarcinoma. Asian Pacific Journal of Cancer Prevention, vol. 14, no. 1, pp. 557-563, 2013
61. Z.Wu, T. Boonmars, S. Boonjaraspinyo et al. Candidate genes involving in tumorigenesis of cholangiocarcinoma induced by Opisthorchis viverrini infection. Parasitology Research, vol. 109, no. 3, pp. 657-673, 2011
62. K. Komatsu, Y. Kobune-Fujiwara, A. Andoh et al. Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma. British Journal of Cancer, vol. 83, no. 6, pp. 769-774, 2000
63. Y. Dai. Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature. Expert Opinion onTherapeutic Patents, vol. 20, no. 7, pp. 885-907, 2010
64. C.-W. Tong, J.-L. Wang, M.-S. Jiang, C.-H. Hsu, W.-T. Chang, and A.-M. Huang. Novel genes that mediate nuclear respiratory factor 1-regualted neurite outgrowth in neuroblastoma IMR-32 cells. Gene, vol. 515, no. 1, pp. 62-70, 2013
65. I. Berger and Y. Shaul. Structure and function of human jun-D. Oncogene, vol. 6, no. 4, pp. 561-566, 1991
66. T. D. Gilmore. Introduction to NF-B: players, pathways, perspectives. Oncogene, vol. 25, no. 51, pp. 6680-6684, 2006
67. G.Morris-Stiff, M. Teli, N. Jardine, andM. C. A. Puntis. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease. Hepatobiliary & Pancreatic Diseases International, vol. 8, no. 6, pp. 620-626, 2009
68. H.-J. Kim, M.-H. Kim, S.-J. Myung et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. American Journal of Gastroenterology, vol. 94, no. 7, pp. 1941-1946, 1999
69. S. Singh, S.-J. Tang, J. Sreenarasimhaiah, L. F. Lara, and A. Siddiqui. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Digestive Diseases and Sciences, vol. 56, no. 8, pp. 2491-2496, 2011
70. A. H. Patel, D. M. Harnois, G. G. Klee, N. F. Larusso, and G. J. Gores. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. American Journal of Gastroenterology, vol. 95, no. 1, pp. 204-207, 2000
71. A. Farina, J.-M. Dumonceau, J.-L. Frossard, A. Hadengue, D. F. Hochstrasser, and P. Lescuyer. Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer. Journal of Proteome Research, vol. 8, no. 1, pp. 159-169, 2009
72. T. Janvilisri, K. Leelawat, S. Roytrakul, A. Paemanee, and R. Tohtong. Novel serum biomarkers to differentiate cholangiocarcinoma from benign biliary tract diseases using a proteomic approach. Disease Markers, vol. 2015, Article ID 105358, 11 pages, 2015
73. J. C.Mertens, C. D. Fingas, J. D. Christensen et al. Therapeutic effects of deleting cancer-Associated fibroblasts in cholangiocarcinoma. Cancer Research, vol. 73, no. 2, pp. 897-907, 2013
74. T. O. Lankisch, J. Metzger, A. A. Negm et al. Bile proteomic profiles differentiate cholangiocarcinoma fromprimary sclerosing cholangitis and choledocholithiasis. Hepatology, vol. 53, no. 3, pp. 875-884, 2011
75. Q. Wu, C.-Z. Liu, L.-Y. Tao et al. The clinicopathological and prognostic impact of 14-3-3 protein isoforms expression in human cholangiocarcinoma by immunohistochemistry. Asian Pacific Journal of Cancer Prevention, vol. 13, no. 4, pp. 1253-1259, 2012
76. H. Hermeking. The 14-3-3 cancer connection. Nature Reviews Cancer, vol. 3, no. 12, pp. 931-943, 2003
77. Z. Hou, H. Peng, D. E. White et al. 14-3-3 binding sites in the snail protein are essential for snail-mediated transcriptional repression and epithelial-mesenchymal differentiation. Cancer Research, vol. 70, no. 11, pp. 4385-4393, 2010
78. R. Kalluri and E. G. Neilson. Epithelial-mesenchymal transition and its implications for fibrosis. Journal of Clinical Investigation, vol. 112, no. 12, pp. 1776-1784, 2003
79. C. Zhang, L.-X. Liu, Z.-R.Dong et al. Up-regulation of 14-3-3 expression in intrahepatic cholangiocarcinoma and its clinical implications. Tumor Biology, vol. 36, no. 3, pp. 1781-1789, 2015
80. Y. Shi, X. Deng, Q. Zhan et al. A prospective proteomic-based study for identifying potential biomarkers for the diagnosis of cholangiocarcinoma. Journal ofGastrointestinal Surgery, vol. 17, no. 9, pp. 1584-1591, 2013
81. S. Maeda, T. Morikawa, T. Takadate et al. Mass spectrometrybased proteomic analysis of formalin-fixed paraffin-embedded extrahepatic cholangiocarcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2015
82. D. Kobayashi, S. Koshida, R.Moriai, N. Tsuji, and N.Watanabe. Olfactomedin 4 promotes S-phase transition in proliferation of pancreatic cancer cells. Cancer Science, vol. 98, no. 3, pp. 334-340, 2007
83. U. Navaneethan, V. Lourdusamy, P. Gk Venkatesh, B. Willard, M. R. Sanaka, and M. Parsi. Bile proteomics for differentiation of malignant from benign biliary strictures: a pilot study. Gastroenterology Report (Oxford), vol. 3, no. 2, pp. 136-143, 2015
84. N. Albiin, I. C. P. Smith, U. Arnelo et al. Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis. Acta Radiologica, vol. 49, no. 8, pp. 855-862, 2008
85. R. M. Kaikaus, N. M. Bass, and R. K.Ockner. Functions of fatty acid binding proteins. Experientia, vol. 46, no. 6, pp. 617-630, 1990
86. A. W. Zimmerman and J. H. Veerkamp. New insights into the structure and function of fatty acid-binding proteins. Cellular and Molecular Life Sciences, vol. 59, no. 7, pp. 1096-1116, 2002
87. L. True, I. Coleman, S. Hawley et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 29, pp. 10991-10996, 2006
88. J. B. Andersen and S. S. Thorgeirsson. Genetic profiling of intrahepatic cholangiocarcinoma. Current Opinion in Gastroenterology, vol. 28, no. 3, pp. 266-272, 2012
89. K.Wosikowski, D. Schuurhuis, K. Johnson et al. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. Journal of the National Cancer Institute, vol. 89, no. 20, pp. 1505-1515, 1997
90. G.-H. Lai, Z. Zhang, X.-N. Shen et al. erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology, vol. 129, no. 6, pp. 2047-2057, 2005
91. A. E. Sirica. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World Journal of Gastroenterology, vol. 14, no. 46, pp. 7033-7058, 2008
92. D. Yoshikawa, H. Ojima, M. Iwasaki et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. British Journal of Cancer, vol. 98, no. 2, pp. 418-425, 2008
93. C. K. Ong, C. Subimerb, C. Pairojkul et al. Exome sequencing of liver fluke-Associated cholangiocarcinoma. Nature Genetics, vol. 44, no. 6, pp. 690-693, 2012
94. D. G. Kirsch and M. B. Kastan. Tumor-suppressor p53: implications for tumor development and prognosis. Journal of Clinical Oncology, vol. 16, no. 9, pp. 3158-3168, 1998
95. T. Soussi. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Annals of the New York Academy of Sciences, vol. 910, no. 1, pp. 121-139, 2000
96. E. Steels, M. Paesmans, T. Berghmans et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-Analysis. European Respiratory Journal, vol. 18, no. 4, pp. 705-719, 2001
97. J.Wang, X.Wang, S.Xie et al. P53 status andits prognostic role in extrahepatic bile duct cancer: a meta-Analysis of published studies. Digestive Diseases and Sciences, vol. 56, no. 3, pp. 655-662, 2011
98. S. Levi, A. Urbano-Ispizua, R. Gill et al. Multiple K-ras codon 12mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Research, vol. 51, no. 13, pp. 3497-3502, 1991
99. K. Ohashi, M. Tsutsumi, Y. Nakajima, H. Nakano, and Y. Konishi. Ki-ras point mutations and proliferation activity in biliary tract carcinomas. British Journal of Cancer, vol. 74, no. 6, pp. 930-935, 1996
100. J. B. Andersen, B. Spee, B. R. Blechacz et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology, vol. 142, no. 4, pp. 1021-e15, 2012
101. D. Sia, Y. Hoshida, A. Villanueva et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology, vol. 144, no. 4, pp. 829-840, 2013
102. R. F. Xu, J.P. Sun, S.R.Zhang et al. KRAS and PIK3CAbut not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. Biomedicine & Pharmacotherapy, vol. 65, no. 1, pp. 22-26, 2011
103. D. Sia, V. Tovar, A. Moeini, and J. M. Llovet. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene, vol. 32, no. 41, pp. 4861-4870, 2013
104. A. Tannapfel, F. Sommerer, M. Benicke et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut, vol. 52, no. 5, pp. 706-712, 2003
105. M. Miyaki and T. Kuroki. Role of Smad4 (DPC4) inactivation in human cancer. Biochemical and Biophysical Research Communications, vol. 306, no. 4, pp. 799-804, 2003
106. X.-Q. Yan, W. Zhang, B.-X. Zhang, H.-F. Liang, W.-G. Zhang, and X.-P. Chen. Inactivation of Smad4 is a prognostic factor in intrahepatic cholangiocarcinoma. Chinese Medical Journal, vol. 126, no. 16, pp. 3039-3043, 2013
107. D. R. Borger, K.K. Tanabe, K. C. Fan et al. Frequent Mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. The Oncologist, vol. 17, no. 1, pp. 72-79, 2012
108. B. R. Kipp, J. S.Voss, S. E. Kerr et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Human Pathology, vol. 43, no. 10, pp. 1552-1558, 2012
109. P. Wang, Q. Dong, C. Zhang et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene, vol. 32, no. 25, pp. 3091-3100, 2013
110. C. R. Churi, R. Shroff, Y. Wang et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS ONE, vol. 9, no. 12, Article ID e115383, 2014
111. M. Miyamoto, H. Ojima, M. Iwasaki et al. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. British Journal of Cancer, vol. 105, no. 1, pp. 131-138, 2011
112. M. P. Socoteanu, F. Mott, G. Alpini, and A. E. Frankel. c-Met targeted therapy of cholangiocarcinoma. World Journal of Gastroenterology, vol. 14, no. 19, pp. 2990-2994, 2008
113. T. Terada, Y. Nakanuma, and A. E. Sirica. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Human Pathology, vol. 29, no. 2, pp. 175-180, 1998
114. J.W. Harbour, M. D. Onken, E. D. O. Roberson et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science, vol. 330, no. 6009, pp. 1410-1413, 2010
115. T. H. Van Essen, S. Van Pelt, M. Versluis et al. Prognostic parameters in uveal melanoma and their association with BAP1 expression. British Journal of Ophthalmology, vol. 98, no. 12, pp. 1738-1743, 2014
116. C. I. Dumur, D. J. W. Campbell, J. L. DeWitt, R. A. Oyesanya, and A. E. Sirica. Differential gene expression profiling of cultured neu-transformed versus spontaneously-transformed rat cholangiocytes and of corresponding cholangiocarcinomas. Experimental and Molecular Pathology, vol. 89, no. 3, pp. 227-235, 2010
117. G. Faa, P. Van Eyken, T. Roskams et al. Expression of cytokeratin 20 in developing rat liver and in experimental models of ductular and oval cell proliferation. Journal of Hepatology, vol. 29, no. 4, pp. 628-633, 1998
118. K. Itatsu, Y. Zen, J. Yamaguchi et al. Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts. Human Pathology, vol. 39, no. 5, pp. 710-719, 2008
119. S. Miwa, S.-I. Miyagawa, J. Soeda, and S. Kawasaki. Matrix metalloproteinase-7 expression and biologic aggressiveness of cholangiocellular carcinoma. Cancer, vol. 94, no. 2, pp. 428-434, 2002
120. H.-J. Yoo, B.-R. Yun, J.-H. Kwon et al. Genetic and expression alterations in association with the sarcomatous change of cholangiocarcinoma cells. Experimental&MolecularMedicine, vol. 41, no. 2, pp. 102-115, 2009
121. M. J. Gu and J. H. Choi. Epithelial-mesenchymal transition phenotypes are associated with patient survival in intrahepatic cholangiocarcinoma. Journal of Clinical Pathology, vol. 67, no. 3, pp. 229-234, 2014
122. H. Isomoto. Epigenetic alterations associated with cholangiocarcinoma (Review). Oncology Reports, vol. 22, no. 2, pp. 227-232, 2009
123. R. Sriraksa, C. Zeller, W. Dai et al. Aberrant DNAmethylation at genes associated with a stem cell-like phenotype in cholangiocarcinoma tumors. Cancer Prevention Research, vol. 6, no. 12, pp. 1348-1355, 2013
124. B. Goeppert, C. Konermann, C. R. Schmidt et al. Global alterations of DNA methylation in cholangiocarcinoma target theWnt signaling pathway. Hepatology, vol. 59, no. 2, pp. 544-554, 2014
125. J. B. Andersen. Molecular pathogenesis of intrahepatic cholangiocarcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, vol. 22, no. 2, pp. 101-113, 2015
126. A. Budhu, J. Ji, and X. W. Wang. The clinical potential of microRNAs. Journal of Hematology and Oncology, vol. 3, no. 1, article 37, 2010
127. X. W. Wang, N. H. H. Heegaard, and H. Ørum. MicroRNAs in liver disease. Gastroenterology, vol. 142, no. 7, pp. 1431-1443, 2012
128. Y. Kawahigashi, T. Mishima, Y. Mizuguchi et al. microRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs. Journal of Nippon Medical School, vol. 76, no. 4, pp. 188-197, 2009
129. F. M. Selaru, A. V. Olaru, T. Kan et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology, vol. 49, no. 5, pp. 1595-1601, 2009
130. N. Oishi, M. R. Kumar, S. Roessler et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology, vol. 56, no. 5, pp. 1792-1803, 2012
131. L. Chen, H.-X. Yan, W. Yang et al. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. Journal of Hepatology, vol. 50, no. 2, pp. 358-369, 2009
132. Y.-H. Qiu, Y.-P. Wei, N.-J. Shen et al. miR-204 Inhibits epithelial to mesenchymal transition by targeting slug in intrahepatic cholangiocarcinoma cells. Cellular Physiology and Biochemistry, vol. 32, no. 5, pp. 1331-1341, 2013
133. I. A. Darby, K. Vuillier-Devillers, é. Pinault et al. Proteomic analysis of differentially expressed proteins in peripheral cholangiocarcinoma. Cancer Microenvironment, vol. 4, no. 1, pp. 73-91, 2011
134. T. Tsujino, I. Seshimo, H. Yamamoto et al. Stromalmyofibroblasts predict disease recurrence for colorectal cancer. Clinical Cancer Research, vol. 13, no. 7, pp. 2082-2090, 2007
135. K. Utispan, P.Thuwajit, Y. Abiko et al. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Molecular Cancer, vol. 9, article 13, 2010
136. H. Kawase, K. Fujii, M. Miyamoto et al. Differential LCMS-based proteomics of surgical human cholangiocarcinoma tissues. Journal of Proteome Research, vol. 8, no. 8, pp. 4092-4103, 2009
137. D. A. Lauffenburger and A. F. Horwitz. Cell migration: a physically integrated molecular process. Cell, vol. 84, no. 3, pp. 359-369, 1996
138. K. Honda, T. Yamada, R. Endo et al. Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. The Journal of Cell Biology, vol. 140, no. 6, pp. 1383-1393, 1998
139. R. H. Kim, M. Peters, Y. Jang et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell, vol. 7, no. 3, pp. 263-273, 2005
140. D. Nagakubo, T. Taira, H. Kitaura et al. DJ-1, a novel oncogene which transformsmouse NIH3T3 cells in cooperation with ras. Biochemical and Biophysical Research Communications, vol. 231, no. 2, pp. 509-513, 1997
141. L. Cao, R. T. Taggart, I.M. Berquin, K.Moin, D. Fong, and B. F. Sloane. Human gastric adenocarcinoma cathepsin B: isolation and sequencing of full-length cDNAs and polymorphisms of the gene. Gene, vol. 139, no. 2, pp. 163-169, 1994
142. J. S. Mort and D. J. Buttle. Cathepsin B. The International Journal of Biochemistry & Cell Biology, vol. 29, no. 5, pp. 715-720, 1997
143. Z. Li and P. Srivastava. Appendix 1T Heat-shock proteins. in Current Protocols in Immunology, appendix 1, John Wiley & Sons, 2004
144. A. Silsirivanit, K. Sawanyawisuth, G. J. Riggins, and C. Wongkham. Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches. Journal of Hepato-Biliary-Pancreatic Sciences, vol. 21, no. 6, pp. 388-396, 2014
145. R. Thanan, S. Oikawa, P. Yongvanit et al. Inflammationinduced protein carbonylation contributes to poor prognosis for cholangiocarcinoma. Free Radical Biology and Medicine, vol. 52, no. 8, pp. 1465-1472, 2012
146. S. Boonjaraspinyo, T. Boonmars, S. Kaewkes et al. Downregulated expression of HSP70 in correlation with clinicopathology of cholangiocarcinoma. Pathology and Oncology Research, vol. 18, no. 2, pp. 227-237, 2012
147. T. Shirota, H. Ojima, N. Hiraoka et al. Heat shock protein 90 is a potential therapeutic target in cholangiocarcinoma. Molecular CancerTherapeutics, 2015
148. C. Srisomsap, P. Sawangareetrakul, P. Subhasitanont et al. Proteomic analysis of cholangiocarcinoma cell line. Proteomics, vol. 4, no. 4, pp. 1135-1144, 2004
149. R. Lotan, H. Ito, W. Yasui, H. Yokozaki, D. Lotan, and E. Tahara. Expression of a 31-kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. International Journal of Cancer, vol. 56, no. 4, pp. 474-480, 1994
150. X. Sanjuan, P. L. Fernandez, A. Castells et al. Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology, vol. 113, no. 6, pp. 1906-1915, 1997
151. D. M. Skrincosky, H. J. Allen, and R. J. Bernacki. Galaptinmediated adhesion of human ovarian carcinoma A121 cells and detection of cellular galaptin-binding glycoproteins. Cancer Research, vol. 53, no. 11, pp. 2667-2675, 1993
152. X.-C. Xu, A. K. El-Naggar, and R. Lotan. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. The American Journal of Pathology, vol. 147, no. 3, pp. 815-822, 1995
153. P. Yonglitthipagon, C. Pairojkul, V. Bhudhisawasdi, J.Mulvenna, A. Loukas, and B. Sripa. Proteomics-based identification of -enolase as a potential prognostic marker in cholangiocarcinoma. Clinical Biochemistry, vol. 45, no. 10-11, pp. 827-834, 2012
154. A. M. Gomes, M. P. Stelling, and M. S. G. Pavão. Heparan sulfate and heparanase as modulators of breast cancer progression. BioMed Research International, vol. 2013, Article ID 852093, 11 pages, 2013
155. J. O. Nyalwidhe, L. R. Betesh, T. W. Powers et al. Increased bisecting N-Acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression. Proteomics-Clinical Applications, vol. 7, no. 9-10, pp. 677-689, 2013
156. A. Silsirivanit, N. Araki, C. Wongkham et al. CA-S27: a novel Lewis a associated carbohydrate epitope is diagnostic and prognostic for cholangiocarcinoma. Cancer Science, vol. 104, no. 10, pp. 1278-1284, 2013
157. S. Wongkham and A. Silsirivanit. State of serum markers for detection of cholangiocarcinoma. Asian Pacific Journal of Cancer Prevention, vol. 13, supplement, pp. 17-27, 2012
158. D.W.Kufe. Mucins in cancer: function, prognosis and therapy. Nature Reviews Cancer, vol. 9, no. 12, pp. 874-885, 2009
159. F. Levitin, O. Stern, M.Weiss et al. The MUC1 SEA module is a self-cleaving domain. The Journal of Biological Chemistry, vol. 280, no. 39, pp. 33374-33386, 2005
160. M. J. L. Ligtenberg, L. Kruijshaar, F. Buijs, M. Van Meijer, S. V. Litvinov, and J. Hilkens. Cell-Associated episialin is a complex containing two proteins derived from a common precursor. The Journal of Biological Chemistry, vol. 267, no. 9, pp. 6171-6177, 1992
161. B. Macao, D. G. A. Johansson, G. C. Hansson, and T. Härd. Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin. Nature Structural and Molecular Biology, vol. 13, no. 1, pp. 71-76, 2006
162. M. Yamamoto, A. Bharti, Y. Li, and D. Kufe. Interaction of the DF3/MUC1 breast carcinoma-Associated antigen and -catenin in cell adhesion. The Journal of Biological Chemistry, vol. 272, no. 19, pp. 12492-12494, 1997
163. N. Matsumura, M. Yamamoto, A. Aruga, K. Takasaki, and M. Nakano. Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer, vol. 94, no. 6, pp. 1770-1776, 2002
164. C. Boonla, B. Sripa, P. Thuwajit et al. MUC1 and MUC5AC mucin expression in liver fluke-Associated intrahepatic cholangiocarcinoma. World Journal of Gastroenterology, vol. 11, no. 32, pp. 4939-4946, 2005
165. H. Shibahara, S. Tamada, M. Higashi et al. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinomamass forming type. Hepatology, vol. 39, no. 1, pp.220-229, 2004
166. T. Lang, G. C. Hansson, and T. Samuelsson. Gel-forming mucins appeared early in metazoan evolution. Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 41, pp. 16209-16214, 2007
167. S.-M. Hong, H. Cho, C. A. Moskaluk, H. F. Frierson Jr., E. Yu, and J. Y. Ro. CDX2 and MUC2 protein expression in extrahepatic bile duct carcinoma. American Journal of Clinical Pathology, vol. 124, no. 3, pp. 361-370, 2005
168. K.-S. Suh, S.-H. Chang, H.-J. Lee, H. R. Roh, S. H. Kim, and K. U. Lee. Clinical outcomes and apomucin expression of intrahepatic cholangiocarcinoma according to gross morphology. Journal of the American College of Surgeons, vol. 195, no. 6, pp. 782-789, 2002
169. S. Tamada, M. Goto, M. Nomoto et al. Expression of MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: its relationship with tumor progression and prognosis. Pathology International, vol. 52, no. 11, pp. 713-723, 2002
170. M. Higashi, S. Yonezawa, J. J. L. Ho et al. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology, vol. 30, no. 6, pp. 1347-1355, 1999
171. A. W. Sharif, H. R. T.Williams, T. Lampejo et al. Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy. HPB, vol. 12, no. 6, pp. 396-402, 2010
172. S. A. Khan, H. C. Thomas, B. R. Davidson, and S. D. Taylor-Robinson. Cholangiocarcinoma. The Lancet, vol. 366, no. 9493, pp. 1303-1314, 2005
173. D. Komichi, S. Tazuma, T. Nishioka, H. Hyogo, and K. Chayama. Glycochenodeoxycholate plays a carcinogenic role in immortalized mouse cholangiocytes via oxidative DNA damage. Free Radical Biology and Medicine, vol. 39, no. 11, pp. 1418-1427, 2005
174. F. Hirschhaeuser, U. G. A. Sattler, and W. Mueller-Klieser. Lactate: a metabolic key player in cancer. Cancer Research, vol. 71, no. 22, pp. 6921-6925, 2011
175. P. P. Hsu and D. M. Sabatini. Cancer cellmetabolism: warburg and beyond. Cell, vol. 134, no. 5, pp. 703-707, 2008
176. M. G. V. Heiden, L. C. Cantley, and C. B. Thompson. Understanding theWarburg effect: the metabolic requirements of cell proliferation. Science, vol. 324, no. 5930, pp. 1029-1033, 2009
177. A.-G.Wang, S. Y. Yoon, J.-H. Oh et al. Identification of intrahepatic cholangiocarcinoma related genes by comparison with normal liver tissues using expressed sequence tags. Biochemical and Biophysical Research Communications, vol. 345, no. 3, pp. 1022-1032, 2006
178. M.-C. Lai, D.-R. Yang, and M.-J. Chuang. Regulatory factors associated with synthesis of the osmolyte glycine betaine in the halophilic methanoarchaeonMethanohalophilus portucalensis. Applied andEnvironmentalMicrobiology, vol. 65, no. 2, pp. 828-833, 1999
179. Y.-C. Huang, M. Chen, Y.-M. Shyr et al. Glycine N-methyltransferase is a favorable prognostic marker for human cholangiocarcinoma. Journal of Gastroenterology and Hepatology, vol. 23, no. 9, pp. 1384-1389, 2008
180. F. Yang, J. B. Lum, J. R.McGill et al. Human transferrin: cDNA characterization and chromosomal localization. Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 9, pp. 2752-2756, 1984
181. J.-Y. Lee, Y.-N. Park, K.-O. Uhm, S.-Y. Park, and S.-H. Park. Genetic alterations in intrahepatic cholangiocarcinoma as revealed by degenerate oligonucleotide primed PCRcomparative genomic hybridization. Journal of KoreanMedical Science, vol. 19, no. 5, pp. 682-687, 2004
182. K.-O. Uhm, Y.-N. Park, J.-Y. Lee, D.-S. Yoon, and S.-H. Park. Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization. Cancer Genetics and Cytogenetics, vol. 157, no. 1, pp. 37-41, 2005
183. K. Shiraishi, K. Okita, T. Harada et al. Comparative genomic hybridization analysis of genetic aberrations associated with development and progression of biliary tract carcinomas. Cancer, vol. 91, no. 3, pp. 570-577, 2001
184. M. J. Borad, M. D. Champion, J. B. Egan et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genetics, vol. 10, no. 2, Article ID e1004135, 2014
185. S. Zou, J. Li, H. Zhou et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nature Communications, vol. 5, article 5696, 2014
186. J. Harder, O. Waiz, F. Otto et al. EGFR and HER2 expression in advanced biliary tract cancer. World Journal ofGastroenterology, vol. 15, no. 36, pp. 4511-4517, 2009
187. S. Jang, S.-M. Chun, S.-M. Hong et al. High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases. Modern Pathology, vol. 27, no. 5, pp. 731-739, 2014
188. M. Simbolo, M. Fassan, A. Ruzzenente et al. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget, vol. 5, no. 9, pp. 2839-2852, 2014
189. G.-Y. Gwak, J.-H. Yoon, C. M. Shin et al. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. Journal of Cancer Research and Clinical Oncology, vol. 131, no. 10, pp. 649-652, 2005
190. J. B. Andersen, B. Spee, B. R. Blechacz et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology, vol. 142, no. 4, pp. 1021.e15-1031.e15, 2012
191. S. Yabuuchi, Y. U. Katayose, O. D. A. Akira et al. ZD1839 stabilizes p27kip1 and enhances radiosensitivity in cholangiocarcinoma cell lines. Anticancer Research, vol. 29, no. 4, pp. 1169-1180, 2009
192. G. S. Papaetis and K. N. Syrigos. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs, vol. 23, no. 6, pp. 377-389, 2009
193. G. Aparicio-Gallego, M. Blanco, A. Figueroa et al. New insights into molecular mechanisms of sunitinib-Associated side effects. Molecular Cancer Therapeutics, vol. 10, no. 12, pp. 2215-2223, 2011
194. R. Schmieder, J.Hoffmann, M. Becker et al. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. International Journal of Cancer, vol. 135, no. 6, pp. 1487-1496, 2014
195. M. A. Fabian, W. H. Biggs III, D. K. Treiber et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnology, vol. 23, no. 3, pp. 329-336, 2005
196. S. M. Wilhelm, J. Dumas, L. Adnane et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. International Journal of Cancer, vol. 129, no. 1, pp. 245-255, 2011
197. S.Wilhelm, C. Carter, M. Lynch et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature ReviewsDrugDiscovery, vol. 5, no. 10, pp. 835-844, 2006
198. T. Waddell and D. Cunningham. Evaluation of regorafenib in colorectal cancer and GIST. The Lancet, vol. 381, no. 9863, pp. 273-275, 2013
199. D. R. Borger, K.K. Tanabe, K. C. Fan et al. Frequent Mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist, vol. 17, no. 1, pp. 72-79, 2012
200. Y. Jiao, T. M. Pawlik, R. A. Anders et al. Exome sequencing identifies frequent inactivatingmutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nature Genetics, vol. 45, no. 12, pp. 1470-1473, 2013
201. M. B. Pappalardi, D. E.McNulty, J.D.Martin et al. Biochemical characterization of human HIF hydroxylases using HIF protein substrates that contain all three hydroxylation sites. Biochemical Journal, vol. 436, no. 2, pp. 363-369, 2011
202. D. Rohle, J. Popovici-Muller, N. Palaskas et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science, vol. 340, no. 6132, pp. 626-630, 2013
203. F.Wang, J. Travins, B. DeLaBarre et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science, vol. 340, no. 6132, pp. 622-626, 2013
204. J. Lamb, E. D. Crawford, D. Peck et al. The connectivitymap: using gene-expression signatures to connect small molecules, genes, and disease. Science, vol. 313, no. 5795, pp. 1929-1935, 2006
205. M.-H. Chen, K.-J. Lin, W.-L. R. Yang et al. Gene expressionbased chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma. Cancer, vol. 119, no. 2, pp. 293-303, 2013
206. K. Kosriwong, T. R. Menheniott, A. S. Giraud, P. Jearanaikoon, B. Sripa, and T. Limpaiboon. Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma. World Journal of Gastroenterology, vol. 17, no. 12, pp. 1631-1641, 2011
207. N. S. Sandanayake, J. Sinclair, F. Andreola et al. A combination of serum leucine-rich alpha-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. British Journal of Cancer, vol. 105, no. 9, pp. 1370-1378, 2011
208. H. Isomoto, S. Kobayashi, N. W. Werneburg et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology, vol. 42, no. 6, pp. 1329-1338, 2005
209. G. W. Kim, N. R. Lee, R. H. Pi et al. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Archives of Pharmacal Research, vol. 38, no. 5, pp. 575-584, 2015
210. H. S. Abou-Auda and W. Sakr. Tocilizumab: a new antirheumatic drug. Saudi Pharmaceutical Journal, vol. 18, no. 4, pp. 257-259, 2010
211. F. Hayakawa, K. Sugimoto, Y. Harada et al. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-Addictive oncokinases. Blood Cancer Journal, vol. 3, no. 11, article e166, 2013
212. Y. Kim, J. Hsu, T. Zhou et al. Abstract LB-317: potent in vivo pharmacology ofAZD9150, a next-generation, constrained ethyl-modified antisense oligonucleotide targeting STAT3 in multiple preclinical cancermodels. Cancer Research, vol. 73, no. 8, supplement, p. LB-317, 2013
213. A. W. Sharif, H. R. Williams, T. Lampejo et al. Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy. HPB, vol. 12, no. 6, pp. 396-402, 2010
214. A. Van Helvoort, A. J. Smith, H. Sprong et al. MDR1 Pglycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell, vol. 87, no. 3, pp. 507-517, 1996
215. T. H. Mauad, C. M. J. Van Nieuwkerk, K. P. Dingemans et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene a novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. The American Journal of Pathology, vol. 145, no. 5, pp. 1237-1245, 1994
216. E. Zigmond, A. Ben Yaacov, H. Lee et al. Suppression of hepatocellular carcinoma by inhibition of overexpressed ornithine aminotransferase. ACS Medicinal Chemistry Letters, vol. 6, no. 8, pp. 840-844, 2015